About rigel pharmaceutical - RIGL
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
RIGL At a Glance
Rigel Pharmaceuticals, Inc.
611 Gateway Boulevard
South San Francisco, California 94080-1985
| Phone | 1-650-624-1100 | Revenue | 294.28M | |
| Industry | Pharmaceuticals: Major | Net Income | 367.02M | |
| Sector | Health Technology | 2025 Sales Growth | 64.148% | |
| Fiscal Year-end | 12 / 2026 | Employees | 174 | |
| View SEC Filings |
RIGL Valuation
| P/E Current | 1.413 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 2.199 |
| Price to Sales Ratio | 2.742 |
| Price to Book Ratio | 2.003 |
| Price to Cash Flow Ratio | 10.67 |
| Enterprise Value to EBITDA | 5.515 |
| Enterprise Value to Sales | 2.397 |
| Total Debt to Enterprise Value | 0.076 |
RIGL Efficiency
| Revenue/Employee | 1,691,275.862 |
| Income Per Employee | 2,109,333.333 |
| Receivables Turnover | 5.685 |
| Total Asset Turnover | 0.559 |
RIGL Liquidity
| Current Ratio | 2.42 |
| Quick Ratio | 2.304 |
| Cash Ratio | 1.561 |
RIGL Profitability
| Gross Margin | 93.333 |
| Operating Margin | 42.635 |
| Pretax Margin | 41.398 |
| Net Margin | 124.718 |
| Return on Assets | 69.655 |
| Return on Equity | 185.944 |
| Return on Total Capital | 82.518 |
| Return on Invested Capital | 156.163 |
RIGL Capital Structure
| Total Debt to Total Equity | 13.616 |
| Total Debt to Total Capital | 11.984 |
| Total Debt to Total Assets | 9.508 |
| Long-Term Debt to Equity | 5.844 |
| Long-Term Debt to Total Capital | 5.143 |